CD274 and neoplasm: Immune checkpoint blockade reestablishes the anti-tumor response and prevents tumor cells from evading immune surveillance by targeting specific molecules such as programmed death receptor 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) (Ribas and Wolchok, 2018).